Adding Patient-Specific Comorbidities May Improve Risk Evaluation in Myelofibrosis
Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.
Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes
Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.
Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia
March 22nd 2023Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.
Investigational Treatments for Refractory RCC Expand Beyond Immunotherapy
February 23rd 2023Brian I. Rini, MD, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy; the potential role of biomarkers in future targeted treatments; and the need for novel mechanisms such as HIF inhibition to meet the needs of patients who don’t respond to immunotherapy or VEGF TKIs.